rewirebio.iobenchmarks
Dataset

DELFI 2019 internally cross-validated cancer detection cohort

DELFI 2019 internally cross-validated cancer detection cohort; bounded primary-source candidate.

Evaluation results

36 evaluations · 246 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: DELFI 2019 internally cross-validated cancer detection tested configurationProtocol: DELFI 2019 internally cross-validated cancer detection protocol
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
73% Sensitivity at 98% specificity
percent · higher

Uncertainty: 95% CI 67 to 79

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

DELFI 2019 internally cross-validated cancer detection

amp-20261007-ctdna-fragmentomics-protocol

Aggregation: Not reported

Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 · PMC6774252 Table 1 T1 Cancer row / 98% specificity columns; Results P15; Methods P34; Extended Data Fig. 7 F11.
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.985 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9805 to 0.9898

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C22; group 'BRCA'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.932 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9073 to 0.9574

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E22; group 'BRCA'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.838 Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7936 to 0.8824

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D22; group 'BRCA'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.99 AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9850 to 0.9951

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C32; group 'CHOL'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.955 Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9289 to 0.9811

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E32; group 'CHOL'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.917 Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8838 to 0.9495

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D32; group 'CHOL'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9991 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C42; group 'CRC'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 1.0000 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E42; group 'CRC'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.993 Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9803 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D42; group 'CRC'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.998 AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9957 to 0.9997

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C62; group 'NSCLC'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 1.0000 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E62; group 'NSCLC'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.95 Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9073 to 0.9927

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D62; group 'NSCLC'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.989 AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9849 to 0.9930

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C72; group 'OV'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.958 Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9293 to 0.9873

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E72; group 'OV'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.82 Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7618 to 0.8782

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D72; group 'OV'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.954 AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9421 to 0.9667

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C82; group 'PAAD'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.873 Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8396 to 0.9054

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E82; group 'PAAD'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.817 Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7751 to 0.8582

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D82; group 'PAAD'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.974 AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9696 to 0.9776

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C12; group 'PANCAN'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.963 AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9435 to 0.9819

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C52; group 'STAD'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.92 Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8875 to 0.9525

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E52; group 'STAD'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.897 Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8586 to 0.9347

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

EDM (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D52; group 'STAD'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.975 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9651 to 0.9843

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

coverage (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C17; group 'BRCA'; row 'coverage'; column 'AUC'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.947 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9280 to 0.9660

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

coverage (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E17; group 'BRCA'; row 'coverage'; column 'Sensitivity @85% specificity'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-11-21-c8bea25e5abb · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified
  • Sample annotations are recorded: not yet verified
  • Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • A pinned run recipe exists: not yet verified
  • Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Independent validation data exist: not yet verified
  • Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Dataset and evaluation context

A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

4 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Population
208 patients with seven cancer types and 215 healthy individuals used for classifier; broader study abstract 236 cancers/245 healthy is not classifier denominator.
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

No field-specific location recorded

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.population

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Split
10-fold cross-validation repeated 10 times; feature selection and model estimation on training folds only
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

No field-specific location recorded

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.split

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Description
DELFI 2019 internally cross-validated cancer detection cohort; bounded primary-source candidate.
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

No field-specific location recorded

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Name
DELFI 2019 internally cross-validated cancer detection cohort
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

No field-specific location recorded

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: name

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID amp-20261007-ctdna-fragmentomics-dataset.

Related records

Suggest a correction